BC Week In Review | Jul 15, 2013
Company News

Advancell, Helsinn deal

Advancell granted Helsinn exclusive, worldwide rights to develop and commercialize ATH008 . The undisclosed topical cream is in development to treat palmoplantar erythrodysesthesia syndrome (PPES) and hand-foot skin reactions (HFSR), which are painful cutaneous reactions to...
BC Week In Review | Apr 25, 2011
Clinical News

ATH008: Phase IIb started

Advancell began a double-blind, placebo-controlled, European Phase IIb trial to evaluate twice-daily 1%, 3% and 8% ATH008 in up to 100 patients with PPES secondary to capecitabine monotherapy. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets capecitabine...
Items per page:
1 - 2 of 2